- Home
- HOLO vs NLSP Comparison
HOLO vs NLSP Comparison
Compare HOLO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- NLSP
- Stock Information
- Founded
- HOLO 2018
- NLSP 2015
- Country
- HOLO China
- NLSP Switzerland
- Employees
- HOLO N/A
- NLSP N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- NLSP Health Care
- Exchange
- HOLO Nasdaq
- NLSP Nasdaq
- Market Cap
- HOLO 24.9M
- NLSP 12.4M
- IPO Year
- HOLO N/A
- NLSP 2021
- Fundamental
- Price
- HOLO $7.09
- NLSP $2.10
- Analyst Decision
- HOLO
- NLSP
- Analyst Count
- HOLO 0
- NLSP 0
- Target Price
- HOLO N/A
- NLSP N/A
- AVG Volume (30 Days)
- HOLO 4.2M
- NLSP 275.3K
- Earning Date
- HOLO 01-01-0001
- NLSP 07-22-2025
- Dividend Yield
- HOLO N/A
- NLSP N/A
- EPS Growth
- HOLO N/A
- NLSP N/A
- EPS
- HOLO N/A
- NLSP N/A
- Revenue
- HOLO $39,771,750.00
- NLSP N/A
- Revenue This Year
- HOLO N/A
- NLSP N/A
- Revenue Next Year
- HOLO N/A
- NLSP N/A
- P/E Ratio
- HOLO N/A
- NLSP N/A
- Revenue Growth
- HOLO 42.62
- NLSP N/A
- 52 Week Low
- HOLO $4.16
- NLSP $1.30
- 52 Week High
- HOLO $608.00
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- HOLO 53.39
- NLSP 46.61
- Support Level
- HOLO $4.84
- NLSP $2.20
- Resistance Level
- HOLO $6.20
- NLSP $3.08
- Average True Range (ATR)
- HOLO 0.46
- NLSP 0.25
- MACD
- HOLO 0.37
- NLSP -0.06
- Stochastic Oscillator
- HOLO 91.11
- NLSP 8.40
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.